Home › NDC Lookup › RxCUI directory › RxCUI 1248013

Docusate sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet [Senexon S] — RxCUI 1248013

RxNorm drug concept · Semantic branded drug
RxCUI 1248013 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1248013
Official nameDocusate sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet [Senexon S]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asDOSS Sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet [Senexon S]; Senexon-S 50 MG / 8.6 MG Oral Tablet
FDA products mapped2
Package NDCs mapped5
Reported Medicaid activity (SDUD)197,480 prescriptions · 37 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Senna: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Senna typically produces a bowel movement within 6 to 12 hours. That's why most people take it at bedtime — so it can do its job overnight and you get results in the morning. If no...
  • How long does it take for senna to work?
  • Senna is designed for short-term, occasional use. You should not use it for more than 1 week unless your doctor specifically tells you it's okay. Using laxatives too often or for t...
  • Laxatives like senna can affect how your body absorbs other medications. To be safe, take senna at least 2 hours before or after any other drugs you use. It's always a good idea to...
📖 Read our full Senna guide →

🕸️ Concept Web — How Docusate sodium 50 MG / sennosides, USP 8.6 MG O... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Docusate sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet [Senexon S] RxCUI 1248013

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Docusate 82003
    • Sennosides, USP 36387
    • Docusate / sennosides, USP 1008340
    • Docusate sodium 71722
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Senexon S 895371
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Docusate / sennosides, USP Oral Tablet 373860
    • Docusate sodium / sennosides, USP Oral Tablet 2649201
    • Docusate / sennosides, USP Oral Product 1160195
    • Docusate / sennosides, USP Pill 1160196
    • Docusate sodium / sennosides, USP Oral Product 2660390
    • Docusate sodium / sennosides, USP Pill 2660734
    • Docusate / sennosides, USP Oral Tablet [Senexon S] 895373
    • Docusate sodium / sennosides, USP Oral Tablet [Senexon S] 2658394
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 17 of 22 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Docusate sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet SCD · 998740
  • Docusate sodium 50 MG SCDC · 836262
  • Sennosides, USP 8.6 MG SCDC · 331847
  • Docusate / sennosides, USP Oral Tablet SCDF · 373860
  • Docusate sodium / sennosides, USP Oral Tablet SCDFP · 2649201
  • Docusate / sennosides, USP Oral Product SCDG · 1160195
  • Docusate / sennosides, USP Pill SCDG · 1160196
  • Docusate sodium / sennosides, USP Oral Product SCDGP · 2660390
  • Docusate sodium / sennosides, USP Pill SCDGP · 2660734

Brand-Name Concepts

  • Docusate sodium 50 MG / sennosides, USP 8.6 MG [Senexon S] SBDC · 1248012
  • Docusate / sennosides, USP Oral Tablet [Senexon S] SBDF · 895373
  • Docusate sodium / sennosides, USP Oral Tablet [Senexon S] SBDFP · 2658394
  • Senexon S Oral Product SBDG · 1178378
  • Senexon S Pill SBDG · 1178379
  • Senexon S BN · 895371

📦 FDA Products & Package NDCs

2 products · 5 package NDCs
5 package NDCs map to RxCUI 1248013 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00536-1247-01 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0536-1247-01) Senexon-S RUGBY LABORATORIES 2019-10-02
00536-1247-10 1000 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0536-1247-10) Senexon-S RUGBY LABORATORIES 2019-10-02
00615-8331-05 15 TABLET, FILM COATED in 1 BLISTER PACK (0615-8331-05) Senexon-S NCS HealthCare of KY, LLC dba Vangard Labs 2024-07-08
00615-8331-28 28 TABLET, FILM COATED in 1 BLISTER PACK (0615-8331-28) Senexon-S NCS HealthCare of KY, LLC dba Vangard Labs 2024-12-26
00615-8331-39 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8331-39) Senexon-S NCS HealthCare of KY, LLC dba Vangard Labs 2020-01-07
Observed labelers: NCS HealthCare of KY, LLC dba Vangard Labs (3) · RUGBY LABORATORIES (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.0312
Range $0.0312–$0.0312 · middle 50% $0.0312–$0.0312 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.